Thymosin alpha(1) application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice.

Beuth J, Schierholz JM, Mayer G

Cancer letters1 Oct 2000Cited by 14 (Europe PMC)

PMID10974400DOI10.1016/s0304-3835(00)00510-3PepBankPUB-10974400

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In tumor-bearing BALB/c mice, daily subcutaneous thymosin alpha‑1 for 7 days increased the number of thymocytes.
In plain wordsIn tumor-bearing mice, thymosin alpha‑1 raised the number of thymus cells.
Peptide
Thymosin alpha-1
Outcome
IncreaseThymocyte number
Study
mousen: not reported in source
BALB/c mice
Outcome group
Immune response · Immune and inflammation
Studied dose
0.01-10 µg per injection per mouse · subcutaneous · 7 daysAs given in this study (mouse).
Source sentences
Summary
Daily subcutaneous application (7 consecutive days, 0.01-10 microg of Talpha(1)/injection per mouse) upregulated the number of thymocytes and peripheral blood cells in tumor bearing mice.
Report a problemFND-1097440001
02AnimalAnimal study (in vivo)Efficacy outcome
In tumor-bearing BALB/c mice, daily subcutaneous thymosin alpha‑1 for 7 days increased the number of peripheral blood cells.
In plain wordsIn tumor-bearing mice, thymosin alpha‑1 raised the number of blood cells.
Peptide
Thymosin alpha-1
Outcome
IncreasePeripheral blood cell number
Study
mousen: not reported in source
BALB/c mice
Outcome group
Immune response · Immune and inflammation
Studied dose
0.01-10 µg per injection per mouse · subcutaneous · 7 daysAs given in this study (mouse).
Source sentences
Summary
Daily subcutaneous application (7 consecutive days, 0.01-10 microg of Talpha(1)/injection per mouse) upregulated the number of thymocytes and peripheral blood cells in tumor bearing mice.
Report a problemFND-1097440002
03AnimalAnimal study (in vivo)Efficacy outcome
In BALB/c mice with experimental liver metastases, thymosin alpha‑1 significantly reduced the metastases on day 14 (P<0.05).
In plain wordsIn mice, thymosin alpha‑1 treatment reduced liver metastases from injected tumor cells.
Peptide
Thymosin alpha-1
Outcome
DecreaseExperimental liver metastases
Study
mousen: not reported in source
BALB/c mice
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneous · 7 daysAs given in this study (mouse).
Source sentences
Summary
Organ colonization, as well as local tumor growth, were investigated on day 14 after tumor cell inoculation, and demonstrated a statistically significant (P<0.05) reduction of experimental liver and lung metastases and local tumor growth for Talpha(1) treated mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Talpha(1) was subcutaneously administered daily for 7 consecutive days starting 24 h after tumor cell challenge.
Report a problemFND-1097440003
04AnimalAnimal study (in vivo)Efficacy outcome
In BALB/c mice with experimental lung metastases, thymosin alpha‑1 significantly reduced the metastases on day 14 (P<0.05).
In plain wordsIn mice, thymosin alpha‑1 treatment reduced lung metastases from injected tumor cells.
Peptide
Thymosin alpha-1
Outcome
DecreaseExperimental lung metastases
Study
mousen: not reported in source
BALB/c mice
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneous · 7 daysAs given in this study (mouse).
Source sentences
Summary
Organ colonization, as well as local tumor growth, were investigated on day 14 after tumor cell inoculation, and demonstrated a statistically significant (P<0.05) reduction of experimental liver and lung metastases and local tumor growth for Talpha(1) treated mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Talpha(1) was subcutaneously administered daily for 7 consecutive days starting 24 h after tumor cell challenge.
Report a problemFND-1097440004
05AnimalAnimal study (in vivo)Efficacy outcome
In BALB/c mice with subcutaneous L-1 sarcoma, thymosin alpha‑1 significantly reduced local tumor growth on day 14 (P<0.05).
In plain wordsIn mice, thymosin alpha‑1 treatment reduced the growth of a local tumor.
Peptide
Thymosin alpha-1
Outcome
DecreaseLocal tumor growth
Study
mousen: not reported in source
BALB/c mice
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneous · 7 daysAs given in this study (mouse).
Source sentences
Summary
Organ colonization, as well as local tumor growth, were investigated on day 14 after tumor cell inoculation, and demonstrated a statistically significant (P<0.05) reduction of experimental liver and lung metastases and local tumor growth for Talpha(1) treated mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Talpha(1) was subcutaneously administered daily for 7 consecutive days starting 24 h after tumor cell challenge.
Report a problemFND-1097440005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.